Obesity and DCIS: New Research Reveals a Different Path to Invasive Breast Cancer

July 7, 2026

If you’ve been diagnosed with ductal carcinoma in situ (DCIS), you have likely encountered one of the most frustrating truths about this diagnosis: doctors still can’t say for certain whether your particular DCIS will stay put or eventually become invasive. That uncertainty drives real decisions — about surgery, radiation, hormone therapy — for the roughly 55,000 to 60,000 women diagnosed with DCIS in the U.S. each year. A new study offers a promising piece of the puzzle, and it comes from an unexpected direction: body weight.

Researchers at the University of Oklahoma’s Stephenson Cancer Center and Harold Hamm Diabetes Center, publishing in The American Journal of Pathology, found that obesity doesn’t just raise the risk of invasive breast cancer — it appears to change the biological route DCIS takes to get there. In other words, cancer may be progressing differently, at a molecular level, in patients with obesity than in patients without it.

Why This Question Matters

DCIS — often called “stage 0” breast cancer — accounts for nearly a quarter of all newly diagnosed breast cancers. It’s not invasive on its own, but it does carry an elevated lifetime risk of developing into invasive ductal carcinoma (IDC). The catch is that not every case of DCIS progresses; researchers estimate that a meaningful share never will. Yet, because there’s currently no reliable way to tell which cases are which, most patients receive similar treatment — surgery, often radiation, sometimes hormone therapy — regardless of their individual risk.

“A significant clinical challenge in DCIS is determining which lesions are most likely to progress to invasive breast cancer so that patients are not overtreated or undertreated,” explained Elizabeth A. Wellberg, PhD, one of the study’s lead investigators. That overtreatment concern is one that resonates throughout the DCIS community: nobody wants to undergo more surgery, more radiation, or more worry than is truly necessary — and nobody wants to be undertreated, either.

What the Researchers Found

To dig into how obesity might shape this process, the team used a cutting-edge technique called spatial transcriptomic profiling — essentially, a way of mapping gene activity across different cell types (epithelial, immune, and connective/stromal tissue) while preserving their location within the tumor. This let them see not just what genes were active, but where, and how different cell populations were communicating with one another as DCIS transitioned toward invasive disease.

In patients without obesity, the tumors followed a more familiar script: rapid cell division and the classic biological changes associated with cancer cells invading nearby tissue. But in patients with obesity, the researchers found something different — a “stress-adaptive” pathway marked by inflammation, altered cellular metabolism, and remodeling of the tissue surrounding the tumor. Immune cells moved in, but rather than fighting the cancer, some appeared to be recruited in ways that helped it grow. Tumor cells also seemed better equipped to survive under stress.

“The changes that the cancer cells are undergoing are allowing them to survive and thrive,” said co-lead investigator Bethany N. Hannafon, PhD.

Importantly, the researchers emphasized that this wasn’t just about the cancer cells themselves. “Invasion appears to involve extensive cooperation between epithelial, stromal, and immune cell populations, and obesity influences all of these compartments as well as the signaling interactions between them,” Dr. Hannafon noted. The tumor, in a sense, recruits its neighborhood.

The team also identified elevated levels of an enzyme called sulfatase 2 (SULF2) in tumors from patients with obesity — a molecular signal that could eventually serve as a marker of risk, and possibly even a future treatment target.

What This Could Mean for Patients

It’s important to be clear about what this study is — and isn’t. The research team examined tissue samples from a relatively small group of patients (15 in the main analysis, with an additional 4 used to confirm the findings), and the authors themselves describe their results as exploratory and “hypothesis generating” rather than definitive. That’s normal for early-stage molecular research — it’s how scientists identify promising leads before testing them in larger, more diverse patient populations — but it does mean this isn’t yet a validated clinical tool. It doesn’t change how DCIS is diagnosed or treated today, and it doesn’t mean that every patient with obesity will develop invasive cancer, or that patients without obesity are without risk. What it does offer is a clearer, biologically grounded hypothesis — and a meaningful step toward more personalized risk assessment down the road.

The researchers hope findings like these will eventually help doctors factor metabolic health — not just tumor characteristics — into how they estimate a patient’s individual risk of progression. As Dr. Wellberg put it, “Molecular indicators of progression need to be interpreted within their local tissue context.” That distinction matters for a growing number of patients: as first author Cole Hladik, PhD, pointed out, roughly half of Americans are projected to have obesity by 2030, “further highlighting the importance of considering a patient’s metabolic health alongside the biology of the tumor itself.”

There’s also a hopeful, forward-looking thread here. Because the researchers found that obesity-driven progression involves multiple cell types working together rather than a single rogue pathway, it opens the door to new research questions: Could a treatment that targets inflammation or metabolic stress interrupt this process? Could SULF2 become a useful biomarker for identifying which DCIS lesions are more likely to progress? Those questions are exactly what the research team plans to pursue next.

The Bigger Picture

This study adds to a growing body of evidence that DCIS is not one disease with one path forward — it’s a spectrum, shaped by each patient’s unique biology, including factors like metabolic health that haven’t traditionally been part of the risk conversation. That’s ultimately good news: the more precisely researchers can map these pathways, the closer we get to a future where DCIS treatment decisions are guided by individual risk, not averages.

If you have questions about your own risk factors, including how weight or metabolic health might factor into your care plan, that’s a conversation worth having with your care team. Research like this is how those conversations get better informed, year after year.